On the way to new oral HAE treatment

At the presentation of the operational update and released financial results for the first fiscal quarter ended 31 July 2020 KalVista Pharmaceuticals, Inc. CEO Andrew Crockett says:

“We are pleased that our KVD900 Phase 2 trial has met its enrollment target and data is expected before the end of this year. We believe KVD900 can bring the first effective and well-tolerated oral on-demand treatment option to patients suffering from HAE attacks. Our portfolio of oral options intended to treat HAE also includes prophylactic treatment candidate KVD824, for which we are completing our formulation studies which include dosing in subjects. We look forward to providing additional pharmacokinetic and pharmacodynamic data for KVD824 later this year in advance of starting a Phase 2 clinical trial. Similar to KVD900, our goal with KVD824 is to conduct a robust Phase 2 trial to provide proof-of-concept and potentially an expedited development pathway. We will provide further details on our plans as we prepare to initiate the trial.”
(Source: KalVista)

2020-09-14T22:29:55+02:00September 14, 2020|HAEi News|